Sign Up
OverviewAPI
The Asia-Pacific EV-based liquid biopsy market is projected to reach $74.75 million by 2032, driven by technological advancements and a focus on personalized medicine. Key players include Horiba Ltd., Takara Bio Inc., and others. The COVID-19 pandemic has impacted the market, leading to operational changes.

Ask a question